Reuters logo
BRIEF-Prometic reports positive interim clinical data from IVIG phase 3 trial
November 22, 2017 / 12:14 PM / 25 days ago

BRIEF-Prometic reports positive interim clinical data from IVIG phase 3 trial

Nov 22 (Reuters) - Prometic Life Sciences Inc

* Prometic reports positive interim clinical data from ongoing intravenous immunoglobulin (IVIG) pivotal phase 3 trial

* Prometic Life Sciences Inc - ‍interim clinical data shows non inferiority to commercially-approved products for primary immunodeficiencies​

* Prometic Life Sciences - ‍clinical data confirmed no significant safety issues, efficacy appeared to be comparable to existing commercial IVIG products​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below